DURHAM, N.C. – Researchers from the HIV Prevention Trials Network (HPTN) announced today that the HPTN 083 clinical trial showed that a pre-exposure prophylaxis (PrEP) regimen containing long-acting cabotegravir (CAB LA) injected once every 8 weeks was superior to daily …
The 23rd International AIDS Conference – also known this year as AIDS 2020: Virtual – is underway this week, as researchers, physicians, and advocates around the globe log in for the world’s largest virtual conference on HIV. The Fenway Institute …
BOSTON, June 30, 2020—An editorial published in The British Journal of Psychiatry calls for the development of alternative psychiatric care frameworks that affirm transgender and gender-diverse (TGD) people without pathologizing them through clinical diagnoses. The editorial was authored by researchers …
A new editorial in the British Journal of Psychology looks at the current state of psychiatric diagnoses – and the limitations of those diagnoses – for transgender and gender-diverse (TGD) patients. It also lays out a vision for a future …
The Fenway Institute is excited to announce our newest COVID-19 study as part of our continuing efforts to aid in the search for a COVID-19 vaccine. This study is aiming to learn more about the COVID-19 infection and how the …
In a historic moment for global LGBTQIA+ rights, the United Nations has issued a report calling for an end to the dangerous and medically-discredited practice of conversion therapy. Conversion therapy practices, the UN states, are “interventions of a wide …
We are pleased to announce that the Health Resources and Services Administration (HRSA)’s Bureau of Primary Health Care has awarded the National LGBT Health Education Center at The Fenway Institute a funding renewal of $1.9 million through 2023.
In addition …
A new paper published May 25 in the journal LGBT Health presents guidelines for providing gender-affirming care of trans masculine patients enrolled in the iPledge program for treatment of severe inflammatory or scarring acne. Recommendations include collecting gender identity data …
Boston, MA, May 18 2020 – Today ViiV Healthcare announced the interim analysis of the HIV Prevention Trials Network (HPTN) 083 study evaluating the safety and efficacy of investigational, long-acting, injectable cabotegravir for HIV prevention. In the study, cabotegravir was …
We are excited to announce that Dr. Jennifer Potter, Director of LGBT Population Health, Co-Chair of The Fenway Institute, and HMS Professor of Medicine at Beth Israel Deaconess Medical Center, has been selected by the Harvard Medical School (HMS) Class …
